Thomas G. Auchincloss is Director at CONCERT PHARMACEUTICALS, INC. (CNCE). They have made 7 open-market trades across 2 companies since 2006, most recently 2023-03-06.
CIK 0001377820
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $110K since 2006, never a sale. Across 7 scored buys the stock is up 11.7% at ninety days, and 9.1 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 57% | 43% | 57% |
| Avg Move | +5.1% | +3.9% | +11.7% |
| Alpha | +5.9% | +5.5% | +9.1% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CNCE | BUY | 2022-06-06 | 2022-06-06 | $4.75 | $29K | -14.0% | -7.1% | +45.1% |
| CNCE | BUY | 2020-03-12 | 2020-03-13 | $8.52 | $13K | +26.7% | +43.2% | +33.1% |
| CNCE | BUY | 2020-02-03 | 2020-02-04 | $10.91 | $11K | -6.9% | -19.5% | -29.7% |
| CNCE | BUY | 2018-11-15 | 2018-11-19 | $11.50 | $12K | +10.3% | -2.3% | +16.0% |
| CNCE | BUY | 2018-11-14 | 2018-11-15 | $11.93 | $12K | +18.6% | +13.0% | +21.8% |
| CNCE | BUY | 2016-05-12 | 2016-05-16 | $10.11 | $20K | +13.4% | +0.6% | -3.7% |
| MBLX | SELL · 10b5-1 | 2007-06-28 | 2007-06-28 | $24.02 | $982K | -12.8% | -0.7% | -0.7% |
| MBLX | BUY | 2006-11-10 | 2006-11-13 | $14.00 | $14K | -12.8% | -0.7% | -0.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.